Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up · inside the Ichimoku cloud · RSI 100 (overbought) · MACD below its signal · at its 52-week high
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month high | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week high | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in BGMD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BGMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BGMD.
TimeframesMixed on the hourly, daily, weekly and monthly.
under a flat 21 EMA
under a flat 21 EMA
pulling back under the 21 EMA
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2023 | -33.3 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −66.7% |
| 2022 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 200.0 | 0.0 | +200.0% |
| 2021 | -22.7 | 149.5 | -25.9 | -1.2 | -39.3 | -29.5 | -18.1 | -37.0 | -54.1 | -99.0 | 0.0 | 0.0 | −99.9% |
| 2020 | 256.2 | 1.8 | 30.9 | -7.8 | -19.3 | -29.2 | 1.0 | -5.9 | 0.5 | -21.5 | 60.0 | 191.7 | +775.0% |
| 2019 | -4.9 | -38.3 | 0.0 | 12.0 | 56.4 | -31.5 | 0.0 | -16.7 | -20.0 | 0.0 | -28.0 | 11.1 | −62.4% |
| 2018 | 158.1 | -18.4 | -2.0 | -29.7 | 10.9 | 30.3 | -53.8 | 2.0 | -21.6 | -12.5 | 35.7 | -25.3 | −31.3% |
| 2017 | 49.5 | 66.7 | -20.0 | -23.6 | -5.0 | -19.0 | 3.6 | -7.6 | 11.1 | -18.0 | -7.3 | -18.4 | −22.8% |
| 2016 | -28.7 | 44.2 | -4.0 | -44.7 | 0.5 | 20.0 | -16.7 | -7.0 | -19.4 | -23.3 | -17.4 | -57.7 | −89.0% |
| 2015 | 129.9 | -32.5 | 13.3 | -13.4 | -4.4 | -17.9 | -18.6 | -59.7 | -43.8 | 48.1 | 8.3 | -43.8 | −80.2% |
| 2014 | 16.3 | 7.4 | 47.7 | -36.5 | -17.2 | 4.0 | -10.1 | -17.3 | -30.2 | -19.6 | 7.4 | -1.9 | −55.7% |
| 2013 | -11.3 | -16.1 | 13.4 | -15.4 | 9.1 | -26.1 | -8.3 | -25.4 | 1.1 | -35.6 | 4.5 | 67.8 | −55.0% |
| 2012 | 28.2 | 27.9 | -9.3 | -5.6 | -19.3 | 30.5 | -4.3 | -40.6 | -7.3 | -37.5 | -37.0 | 59.3 | −51.1% |
| 2011 | -9.8 | -1.2 | -4.9 | 9.8 | -5.4 | -19.8 | -41.2 | 37.7 | -5.1 | 1.7 | −44.8% |
No analyst coverage for this instrument.
BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was incorporated in 2000 and is headquartered in Waltham, Massachusetts.
No recent headlines.